Date: 2010-12-5 17:23:32
Author: Research
Source: Projects
Views:
Comments: 0
Summary:Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in com
Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab to treat patients with ad... Stay informed with the latest.